<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003580" GROUP_ID="PREG" ID="769200051811075281" MERGED_FROM="" MODIFIED="2012-08-08 16:53:34 +0100" MODIFIED_BY="Sonja Henderson" REVIEW_NO="0333" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2012-08-08 16:53:34 +0100" MODIFIED_BY="Sonja Henderson">
<TITLE>Heparin for pregnant women with acquired or inherited thrombophilias</TITLE>
<CONTACT MODIFIED="2012-08-08 16:53:34 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="16053" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mark</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Walker</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>mwalker@ohri.ca</EMAIL_1><EMAIL_2>mwalker99@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><CITY>Ottawa</CITY><ZIP>K1H 8L6</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416 7378222</PHONE_1><FAX_1>+1 416 7378387</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-08-08 16:53:34 +0100" MODIFIED_BY="Sonja Henderson"><PERSON ID="16053" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mark</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Walker</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>mwalker@ohri.ca</EMAIL_1><EMAIL_2>mwalker99@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>University of Ottawa</ORGANISATION><CITY>Ottawa</CITY><ZIP>K1H 8L6</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416 7378222</PHONE_1><FAX_1>+1 416 7378387</FAX_1></ADDRESS></PERSON><PERSON ID="15894" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sarah</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Ferguson</LAST_NAME><POSITION>Resident</POSITION><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><ADDRESS_1>92 College Street</ADDRESS_1><CITY>Toronto</CITY><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON><PERSON ID="15825" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Victoria</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Allen</LAST_NAME><SUFFIX>MSc, MD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>vmallen@is.dal.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>Dalhousie University</ORGANISATION><CITY>Halifax</CITY><REGION>Nova Scotia</REGION><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-08-03 23:56:31 +0100" MODIFIED_BY="Jill V Hampson" NOTES="&lt;p&gt;New studies sought but none found: 7/1/02&lt;/p&gt;&lt;p&gt;Feedback added: 11/13/07&lt;/p&gt;" NOTES_MODIFIED="2012-08-03 23:56:31 +0100" NOTES_MODIFIED_BY="Jill V Hampson">
<UP_TO_DATE>
<DATE DAY="1" MONTH="7" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="8" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="5" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2012-08-04 00:12:06 +0100" MODIFIED_BY="Jill V Hampson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-08-04 00:12:06 +0100" MODIFIED_BY="Jill V Hampson">
<DATE DAY="3" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Search updated. Twenty-three reports added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-10-26 14:47:56 +0000" MODIFIED_BY="Jill V Hampson">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-26 14:47:53 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="19" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2009-10-26 14:47:56 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="19" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Reply from author to previously published feedback.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2008-02-19 15:20:51 +0000" MODIFIED_BY="Sonja Henderson">
<DATE DAY="13" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Feedback from DK Cundiff added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Ministry of Health Career Scientist Award</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-08-07 13:49:21 +0100" MODIFIED_BY="Jill V Hampson">
<SUMMARY MODIFIED="2008-02-19 14:19:25 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-02-19 14:19:17 +0000" MODIFIED_BY="[Empty name]">Heparin for pregnant women with acquired or inherited thrombophilias</TITLE>
<SUMMARY_BODY MODIFIED="2008-02-19 14:19:25 +0000" MODIFIED_BY="[Empty name]">
<P>No evidence from trials on the effects of heparin on pregnancy outcomes for women with a thrombophilia.</P>
<P>Thrombophilias are a group of disorders where the person's blood is prone to thrombosis (clotting). These blood clots can cause life-threatening complications such as DVT (deep vein thrombosis). Thrombophilia can cause a number of serious complications in pregnancy, such as growth restriction, stillbirth and severe pre-eclampsia. Heparin is an anti-clotting drug which thins the blood. It does not seem to have adverse effects on the baby during pregnancy, and few adverse effects on the pregnant woman. However, the review found no trials on the effects of heparin on pregnancy outcomes for women with a thrombophilia.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-08-04 00:11:58 +0100" MODIFIED_BY="Jill V Hampson">
<ABS_BACKGROUND>
<P>Thrombophilias, which are associated with a predisposition to thrombotic events, have been implicated in adverse obstetrical outcomes such as intrauterine growth restriction, stillbirth, severe early onset pre-eclampsia, and placental abruption. Heparin administration in pregnancy may reduce the risk of these events.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the effects of heparin on pregnancy outcomes for women with a thrombophilia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-08-03 23:57:17 +0100" MODIFIED_BY="Jill V Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (July 2002), MEDLINE, EMBASE, CINAHL, Scidex (via OVID Technologies - July 2002) and reference lists and personal files. We updated the search of the Cochrane Pregnancy and Childbirth Group's Trials Register on 3 August 2012 and added the results to the awaiting classification section.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized controlled trials comparing heparin with placebo or no treatment, or randomized controlled trials comparing any two treatments. Quasi randomized studies would be included. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data would be abstracted from identified studies and recorded on a paper form by two reviewers. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>No studies were included.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-08-04 00:11:58 +0100" MODIFIED_BY="Jill V Hampson">
<P>There are no completed trials to determine the effects of heparin on pregnancy outcomes for women with a thrombophilia.</P>
<P>[Note: The 23 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-08-04 00:12:20 +0100" MODIFIED_BY="Jill V Hampson">
<BACKGROUND MODIFIED="2008-02-19 14:52:31 +0000" MODIFIED_BY="Sonja Henderson">
<P>Thrombophilias are a diverse group of coagulation disorders associated with a predisposition to thrombotic (clotting) events. These hypercoagulable states can be either inherited or acquired. Inherited thrombophilias include the prothrombin gene mutation (resulting in increased concentration of prothrombin in plasma) and activated protein C resistance (APCR - almost always secondary to factor V Leiden mutation, which results in failure of inactivation of activated factor V). Other inherited thrombophilias are deficiency of physiological anticoagulants protein C, protein S and antithrombin. Acquired thrombophilias include those associated with antiphospholipid antibodies, generally anticardiolipin antibodies and lupus anticoagulant. Hyperhomocysteinemia (elevated fasting plasma homocysteine) can be inherited or acquired. These disorders have been strongly associated with venous thromboembolism such as deep vein thrombosis and potentially fatal pulmonary embolism. However, a number of recent publications have implicated these disorders in adverse obstetrical events such as intrauterine growth restriction, stillbirth, severe early onset pre-eclampsia, and placental abruption.</P>
<SUBSECTION>
<HEADING LEVEL="2">Pre-eclampsia</HEADING>
<P>Pre-eclampsia, defined as proteinuric hypertension in pregnancy, is a disorder that results from impaired placental development and function. The presence of thrombophilias has been found to significantly increase the risk of developing pre-eclampsia. The prevalence of factor V Leiden mutation, hyperhomocysteinemia and protein S deficiency are increased in women who have a history of pre-eclampsia compared with women with a history of normal obstetric outcome. Published data come from case series (<LINK REF="REF-Dekker-1995" TYPE="REFERENCE">Dekker 1995</LINK>; <LINK REF="REF-Rotmensch-1997" TYPE="REFERENCE">Rotmensch 1997</LINK>; <LINK REF="REF-Kahn-1998" TYPE="REFERENCE">Kahn 1998</LINK>; <LINK REF="REF-Leeda-1998" TYPE="REFERENCE">Leeda 1998</LINK>; <LINK REF="REF-Nagy-1998" TYPE="REFERENCE">Nagy 1998</LINK>) and case control studies of varying size and quality (<LINK REF="REF-Dizon_x002d_Townson-1996" TYPE="REFERENCE">Dizon-Townson 1996</LINK>; <LINK REF="REF-Lindoff-1997" TYPE="REFERENCE">Lindoff 1997</LINK>; <LINK REF="REF-Rajkovic-1997" TYPE="REFERENCE">Rajkovic 1997</LINK>; <LINK REF="REF-Krauss-1998" TYPE="REFERENCE">Krauss 1998</LINK>; <LINK REF="REF-Kupferminc-1999" TYPE="REFERENCE">Kupferminc 1999</LINK>).</P>
<P>The incidence of APCR in women with a history of pre-eclampsia ranges from 16% to 33% (<LINK REF="REF-Dizon_x002d_Townson-1996" TYPE="REFERENCE">Dizon-Townson 1996</LINK>; <LINK REF="REF-Lindoff-1997" TYPE="REFERENCE">Lindoff 1997</LINK>; <LINK REF="REF-Krauss-1998" TYPE="REFERENCE">Krauss 1998</LINK>). The factor V Leiden mutation was found in approximately 60% to 100% of those with APCR, the vast majority being heterozygous for the mutation (<LINK REF="REF-Lindoff-1997" TYPE="REFERENCE">Lindoff 1997</LINK>; <LINK REF="REF-Krauss-1998" TYPE="REFERENCE">Krauss 1998</LINK>). Furthermore, a case control study has reported an 8.9% incidence of APCR in women with pre-eclampsia compared with 4.2% in normal pregnancy controls (<LINK REF="REF-Dizon_x002d_Townson-1996" TYPE="REFERENCE">Dizon-Townson 1996</LINK>). In two other case control studies, the calculated odds ratios and 95% confidence interval for the development of severe pre-eclampsia were 5.3 (1.8 to 15.6) (<LINK REF="REF-Kupferminc-1999" TYPE="REFERENCE">Kupferminc 1999</LINK>) and 4.3 (1.2 to 15.7) (<LINK REF="REF-Nagy-1998" TYPE="REFERENCE">Nagy 1998</LINK>).</P>
<P>Hyperhomocysteinemia has been found to be associated with the development of pre-eclampsia (<LINK REF="REF-Dekker-1995" TYPE="REFERENCE">Dekker 1995</LINK>; <LINK REF="REF-Rajkovic-1997" TYPE="REFERENCE">Rajkovic 1997</LINK>; <LINK REF="REF-Sohda-1997" TYPE="REFERENCE">Sohda 1997</LINK>; <LINK REF="REF-Powers-1998" TYPE="REFERENCE">Powers 1998</LINK>; <LINK REF="REF-Kupferminc-1999" TYPE="REFERENCE">Kupferminc 1999</LINK>). The hyperhomocysteinemia in pre-eclamptic pregnancies has been linked to endothelial activation (<LINK REF="REF-Powers-1998" TYPE="REFERENCE">Powers 1998</LINK>) suggesting that homocysteine may play a role in promoting the endothelial dysfunction seen in pre-eclampsia.</P>
<P>There is less information about the association of other inherited thrombophilias with the risk of pre-eclampsia. In one study, 25% of women with a past history of severe, early-onset pre-eclampsia were found to have protein S deficiency (<LINK REF="REF-Dekker-1995" TYPE="REFERENCE">Dekker 1995</LINK>), several of whom had multiple thrombophilias that included protein S deficiency. The prothrombin gene defect was not significantly associated with pre-eclampsia (odds ratio: 2.2; 95% confidence interval: 0.4 to 13.9) in another study (<LINK REF="REF-Kupferminc-1999" TYPE="REFERENCE">Kupferminc 1999</LINK>). Neither protein C nor antithrombin III deficiencies has been shown to be associated with pre-eclampsia (<LINK REF="REF-Dekker-1995" TYPE="REFERENCE">Dekker 1995</LINK>) although the latter defect is rare in the general population (<LINK REF="REF-Dekker-1995" TYPE="REFERENCE">Dekker 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Placental abruption and placental infarction</HEADING>
<P>There is evidence of an association between thrombophilias and placental abruption but the quality of relevant studies is poor. In a series of 21 women whose index pregnancy was complicated by placental abruption, homocysteine levels were significantly higher than in controls (7.9 versus 5.1 umol/L) (<LINK REF="REF-Owen-1997" TYPE="REFERENCE">Owen 1997</LINK>). However, this study did not categorize the women into those with and without hyperhomocysteinemia - a distinction that would have been more meaningful clinically. Also, this study did not have a clear definition of placental abruption.</P>
<P>Resistance to activated protein C was studied in 27 women with placental abruption (<LINK REF="REF-Wiener_x002d_Megnagi-1998" TYPE="REFERENCE">Wiener-Megnagi 1998</LINK>). In the pregnant women with placental abruption, 17 out of 27 had APCR, compared with five out of 29 controls (odds ratio (OR): 8.16; 95% confidence interval (CI): 3.6 to 12.8). This study used a cut-off of APCR of 2.5 which is much higher than the usual convention. Also, the researchers only performed DNA analysis for factor V Leiden mutation on a small subset of the women.</P>
<P>In a study of 84 women with placental abruption or infarction defined by strict clinical, laboratory and histologic standards, 31% had hyperhomocysteinemia compared with 9% of controls (p 0.05) (<LINK REF="REF-Goddijn_x002d_Wessel-1996" TYPE="REFERENCE">Goddijn-Wessel 1996</LINK>).</P>
<P>De Vries et al (<LINK REF="REF-de-Vries-1997" TYPE="REFERENCE">de Vries 1997</LINK>) found that in a series of 31 women with placental abruption, 65% tested positive for a thrombophilia. They found 27 coagulation abnormalities in 20 women. The thrombophilias that they identified were low protein S, hyperhomocysteinemia and anticardiolipin antibodies.</P>
<P>Placental infarction and the prevalence of factor V Leiden mutation has been studied in a prospective cohort study of 396 women whose placentas were categorized dichotomously as having greater than or equal to, or less than 10% infarction. There was a 10-fold increase in factor V Leiden mutation heterozygote status in the infarction group (<LINK REF="REF-Dizon_x002d_Townson-1997" TYPE="REFERENCE">Dizon-Townson 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Intrauterine growth restriction and stillbirth</HEADING>
<P>Small-for-gestational age babies are typically defined as having birthweights less than the 10th percentile for gestational age, and this group will include babies that are 'growth restricted'. In the large EPCOT (European Prospective Cohort on Thrombophilia) trial, pregnancy outcomes were compared in women with a known thrombophilia (N = 571 women, 1524 pregnancies) and controls (N = 395 women, 1019 pregnancies) (<LINK REF="REF-Preston-1996" TYPE="REFERENCE">Preston 1996</LINK>). Significantly more stillbirths occurred in women with a thrombophilia than in the controls. The highest odds for stillbirth were seen in women with combined thrombophilia defects (OR: 14.3; 95% CI: 2.4 to 86.0). Stillbirths were seen only in women with antithrombin III, protein C, and protein S deficiency.</P>
<P>In the previously cited case series by de Vries et al (<LINK REF="REF-de-Vries-1997" TYPE="REFERENCE">de Vries 1997</LINK>), 56% (10/18) of mothers with stillbirths and 85% (11/13) of mothers with a small-for-gestational age infant had a thrombophilia. They identified abnormalities in protein S, hyperhomocysteinemia, and high anticardiolipin titers in association with these outcomes. In another case control study of genetic thrombophilia in women with complications of pregnancy, 48% (27/56) of mothers with a history of stillbirth or a small-for-gestational age infant with IUGR had a thrombophilia (<LINK REF="REF-Kupferminc-1999" TYPE="REFERENCE">Kupferminc 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Prevention of adverse obstetrical outcomes in women with thrombophilia</HEADING>
<P>There is very little research on the prevention of adverse obstetrical outcomes in women with thrombophilia. Heparin, through its antithrombotic activity, could potentially improve perinatal outcome in these pregnancies. However, one case series where low molecular weight heparin combined with aspirin was used to treat 26 thrombophilic women with a history of pre-eclampsia or fetal growth restriction showed heparin did not have a significant effect on birthweight, pre-eclampsia or fetal growth in the subsequent pregnancy (<LINK REF="REF-Riyazi-1998" TYPE="REFERENCE">Riyazi 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Potential adverse effects of heparin</HEADING>
<P>Heparin does not cross the placenta and does not appear to have teratogenic effects in animal studies. Heparin administration may cause pain and slight bruising at injection sites. The risks of heparin administration seem uncommon but include bleeding, heparin-induced thrombocytopenia (HIT) and heparin-induced osteopenia with fractures.</P>
<P>The aim of this review is to provide up to date information on the potential benefits and harms of heparin in thrombophilic pregnant women.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review was to determine whether or not heparin use in pregnant women with a thrombophilia improved pregnancy outcome. Specifically, the objective was to determine whether or not heparin decreased the incidence of the following perinatal outcomes in women with a thrombophilia:<BR/>
</P>
<UL>
<LI>stillbirth;</LI>
<LI>intrauterine growth restriction; </LI>
<LI>placental abruption;</LI>
<LI>pre-eclampsia.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2012-08-03 23:58:10 +0100" MODIFIED_BY="Jill V Hampson">
<SELECTION_CRITERIA MODIFIED="2009-10-26 14:53:34 +0000" MODIFIED_BY="Jill V Hampson">
<CRIT_STUDIES>
<P>Randomized controlled trials comparing heparin with placebo or no treatment, or randomized controlled trials comparing any two treatments. Quasi randomized studies would be included. Publications in abstract form alone were not considered. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-10-26 14:53:34 +0000" MODIFIED_BY="Jill V Hampson">
<P>Participants were pregnant women with a diagnosis of a thrombophilic disorder. They did not necessarily have a previously poor obstetrical history. Thrombophilias were either inherited or acquired.</P>
<P>Inherited thrombophilias:<BR/>
</P>
<UL>
<LI>factor V Leiden mutation;</LI>
<LI>prothrombin gene mutation;</LI>
<LI>protein S deficiency;</LI>
<LI>protein C deficiency;</LI>
<LI>antithrombin III deficiency.</LI>
</UL>
<P>
<BR/>Acquired thrombophilias:<BR/>
</P>
<UL>
<LI>anticardiolipin antibodies;</LI>
<LI>lupus anticoagulant;</LI>
<LI>hyperhomocysteinemia.</LI>
</UL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P> The intervention was the subcutaneous injection of heparin. We included both unfractionated and low molecular weight heparin. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Outcome measures were either a composite of perinatal morbidity and mortality or individual outcomes including the following:</P>
<UL>
<LI>Stillbirth.</LI>
<LI>Small for gestational age (as a surrogate for intrauterine growth restriction (IUGR)) - which was defined as birthweight less than 10th percentile for gestational age. </LI>
<LI>Placental abruption - significant antepartum hemorrhage in the absence of any other identifiable cause such as placenta previa.</LI>
<LI>Pre-eclampsia was defined as proteinuric hypertension in pregnancy, where blood pressure was greater than 140/90 or 30/15 above baseline with proteinuria, either two plus on dip stick or 300 mg in a 24 hour period.</LI>
<LI>Maternal outcomes included thromboembolic disease and side-effects of treatment.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-08-03 23:58:10 +0100" MODIFIED_BY="Jill V Hampson">
<ELECTRONIC_SEARCHES MODIFIED="2012-08-03 23:58:10 +0100" MODIFIED_BY="Jill V Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (July 2002). We updated this search on 3 August 2012 and added the results to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>weekly searches of EMBASE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and EMBASE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>In addition, we searched the following: MEDLINE, EMBASE, CINAHL and Scidex on 1 July 2002 using the search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> via OVID Technologies.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-10-26 14:59:23 +0000" MODIFIED_BY="Jill V Hampson">
<P>We also searched reference lists and personal files.</P>
<P>We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Data were to be abstracted from identified studies and recorded on a paper form. This would be done by two reviewers. Disagreements would be settled by discussion between the reviewers to reach a consensus. Authors were to be contacted as needed for additional information.</P>
<P>Meta-analyses were to be performed with the fixed effects model. Heterogeneity between trial results was to be assessed using a standard chi-squared test. Odds ratios were to be calculated using the 'Peto method'. </P>
<P>Subgroup analysis would, if appropriate, be performed for the following:<BR/>
</P>
<UL>
<LI>therapeutic versus prophylactic doses of heparin;</LI>
<LI>heparin versus placebo and heparin compared with no treatment.</LI>
</UL>
<P>
<BR/>Studies meeting the inclusion criteria would be assessed for methodological quality using the following attributes:<BR/>
</P>
<UL>
<LI>blinding of randomization;</LI>
<LI>blinding of intervention;</LI>
<LI>complete follow up;</LI>
<LI>blinding of outcome measure;</LI>
<LI>analysis by intention to treat.</LI>
</UL>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-08-04 00:12:20 +0100" MODIFIED_BY="Jill V Hampson">
<STUDY_DESCRIPTION MODIFIED="2012-08-04 00:12:20 +0100" MODIFIED_BY="Jill V Hampson">
<P>No completed studies were included. See the table of <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>. (Twenty-three reports from an updated search in August 2012 have been added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.)</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No completed studies were identified.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>There were no included trials.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>No completed randomised trials were identified.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-08-04 00:12:13 +0100" MODIFIED_BY="Jill V Hampson">
<IMPLICATIONS_PRACTICE>
<P>There is no information from randomised trials which could influence current practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-08-04 00:12:13 +0100" MODIFIED_BY="Jill V Hampson">
<P>Further studies are required to evaluate the effect of heparin on pregnancy outcomes for women with a thrombophilia. Two randomised studies are currently ongoing and may provide additional information.</P>
<P>[Note: The 23 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Dr Arne Ohlsson for his teaching and promotion of the Cochrane Collaboration.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>1. Mark Walker<BR/>Developed and wrote first draft of the protocol and review. One of the reviewers who evaluated the studies identified by the search strategy. <BR/>2. Victoria Allen<BR/>Edited second draft of protocol and review. One of the reviewers who evaluated the studies identified by the search strategy.<BR/>3. Sarah Ferguson<BR/>Edited first draft of protocol and co-wrote second draft of protocol and review. Developed the search strategy to identify appropriate studies for the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2012-08-07 13:49:21 +0100" MODIFIED_BY="[Empty name]">
<P>This review will be updated by a new review team following the publication of a new protocol.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-08-04 00:11:47 +0100" MODIFIED_BY="Jill V Hampson">
<STUDIES MODIFIED="2012-08-04 00:11:47 +0100" MODIFIED_BY="Jill V Hampson">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES MODIFIED="2012-08-04 00:11:47 +0100" MODIFIED_BY="Jill V Hampson">
<STUDY DATA_SOURCE="PUB" ID="STD-Abou_x002d_Nassar-2006" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Abou-Nassar 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abou-Nassar K, Rodger M, Kovacs MJ, Doucette S, Tim R, Kahn S, et al</AU>
<TI>The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia: a randomised trial</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>11 Pt 1</NO>
<PG>262</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abou_x002d_Nassar-2007" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Abou-Nassar 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abou-Nassar K, Kovacs MJ, Kahn SR, Wells P, Doucette S, Ramsay T, et al</AU>
<TI>The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>98</VL>
<NO>1</NO>
<PG>163-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brenner-2002" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Brenner 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brenner B, for theLIVE-ENOXI</AU>
<TI>Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss. The LIVE-ENOX study [abstract]</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>11 Pt 1</NO>
<PG>702a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brenner-2003" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Brenner 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brenner B, Hoffman R, Carp H, Dulitsky M, Samueloff A, Yohai D, et al</AU>
<TI>Enoxaparin treatment improves the gestational outcome of pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study [abstract]</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>11</NO>
<PG>16a</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brenner-2003a" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Brenner 2003a" YEAR="2003">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brenner B, Hoffman R, Carp H, Dulitsky M, Samueloff A, Yohal D, et al</AU>
<TI>Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study [abstract]</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>OC084</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brenner-2005" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Brenner 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brenner B, Bar J, Ellis M, Yarom I, Yohai D, Samueloff A, et al</AU>
<TI>Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the live-enox study</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>2005</YR>
<VL>84</VL>
<NO>3</NO>
<PG>770-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brenner-2005a" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Brenner 2005a" YEAR="2005">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J, LIVE-ENOX I</AU>
<TI>Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the live-enox study [See comment]</TI>
<SO>Journal of Thrombosis &amp; Haemostasis</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>2</NO>
<PG>227-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casele-2005" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Casele 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Casele H</AU>
<TI>Thrombosis prophylaxis in pregnancy (ongoing)</TI>
<SO>Evanston Northwestern Healthcare (www.enh.org) (accessed 14 June 2005)</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chistolini-2006" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Chistolini 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chistolini A, Torelli F, Giancotti A, Pignoloni P, Muto B, Cosimo C, et al</AU>
<TI>Recurrent fetal loss: prospective evaluation of the efficacy of three different thromboprophylaxis regimens: aspirin versus low molecular weight heparin versus low molecular weight heparin plus aspirin [abstract]</TI>
<SO>Hematology Journal</SO>
<YR>2006</YR>
<VL>91</VL>
<NO>Suppl 1</NO>
<PG>146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clemens-2011" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Clemens 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Clemens B</AU>
<TI>Heparin for pregnant women with thrombophilia</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 15 February 2011)</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dendrinos-2007" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Dendrinos 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dendrinos S, Kalogirou I, Makrakis E, Theodoridis T, Mahmound EA, Christopoulou-Cokkinou V, et al</AU>
<TI>Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss</TI>
<SO>Clinical and Experimental Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>34</VL>
<NO>3</NO>
<PG>143-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Vries-2011" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="de Vries 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Vries J, van Pampus MG, Hague WM, Bezemer PD, Joosten JH</AU>
<TI>Fractionated heparin in pregnant women with a history of uteroplacental insuffi ciency and thrombophilia, a randomized trial (The FRUIT Study)</TI>
<SO>Reproductive Sciences</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>3 Suppl 1</NO>
<PG>69A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gates-2004" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Gates 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gates S, Brocklehurst P, Ayers S, Bowler U</AU>
<TI>Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<PG>1296-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kamin-2008" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Kamin 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamin G, Rogenhofer N, Pildner v. Steinberg S, Neuhoffer A, Seeger S, Schleussner E</AU>
<TI>Therapy with dalteparin for habitual abortion - presentation of the ETHiG II-Studie</TI>
<TO>Therapie mit Dalteparin bei habitueller Abortneigung - Vorstellung der ETHiG II-Studie</TO>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>2008</YR>
<VL>68</VL>
<PG>S51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laskin-2009" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Laskin 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al</AU>
<TI>Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial</TI>
<SO>Journal of Rheumatology</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>2</NO>
<PG>279-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodger-2005" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Rodger 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodger MA, Lazo-Langner A, Kahn S, Kovacs M, Robinson S, Blostein M, et al</AU>
<TI>Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD substudy</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>11</NO>
<PG>Abstract no 548</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodger-2006" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Rodger 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodger MA, Kahn S, Cranney A, Hodson A, Kovacs M, Clement AM, et al</AU>
<TI>Prophylactic low molecular weight heparin (LMWH) during pregnancy is not associated with a decrease in bone mineral density (BMD) [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>Suppl 1</NO>
<PG>8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodger-2007" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Rodger 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodger MA, Kahn SR, Cranney A, Hodsman A, Kovacs MJ, Clement AM, et al</AU>
<TI>Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>8</NO>
<PG>1600-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodger-2011" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Rodger 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Rodger MA</AU>
<TI>PROSPER: Postpartum prophylaxis for PE randomized control trial pilot</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 15 February 2011)</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tempfer-2012" MODIFIED="2012-08-04 00:11:47 +0100" MODIFIED_BY="[Empty name]" NAME="Tempfer 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-08-04 00:11:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tempfer CB</AU>
<TI>Heparin for pregnant with thrombophilia</TI>
<SO>http://clinicaltrials.gov/show/NCT01019655</SO>
<YR>(accessed 29 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-08-04 00:11:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-08-04 00:11:47 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01019655"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thaler-2004" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Thaler 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thaler I, Brenner B</AU>
<TI>Efficacy of enoxaparin for improving pregnancy outcomes and uteroplacental blood flow in women with thrombophilia and recurrent pregnancy loss [abstract]</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<NO>6 Suppl 1</NO>
<PG>S7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Visser-2009" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Visser 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Visser J, Ulander V, Bloemenkamp K, Kaaja R</AU>
<TI>A randomised controlled multicenter study: the effect of enoxaparin and/or aspirin on prevention of recurrent miscarriage in women with or without thrombophilia, HABENOX-study</TI>
<SO>International Journal of Gynecology &amp; Obstetrics</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>Suppl 2</NO>
<PG>S371</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Visser-2011" MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" NAME="Visser 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-03 23:59:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Visser J, Ulander VM, Helmerhorst FM, Lampinen K, Morin-Papunen L, Bloemenkamp KWM, et al</AU>
<TI>Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia - HABENOX*: a randomised multicentre trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2011</YR>
<VL>105</VL>
<NO>2</NO>
<PG>295-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-de-Vries-2000" NAME="de Vries 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>de Vries</AU>
<TI>Low Molecular weight heparin (FRagmin) in pregnant women with a history of Uteroplacental Insufficiency and Thrombophilia (The Fruit Study)</TI>
<SO>Personal communication</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Rodgers-2000" NAME="Rodgers 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Rodgers M</AU>
<TI>Thrombophilia in Pregnancy Prophylaxis Study (TIPPS)</TI>
<SO>Personal communication</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-10-26 14:54:34 +0000" MODIFIED_BY="Jill V Hampson">
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-de-Vries-1997" NAME="de Vries 1997" TYPE="JOURNAL_ARTICLE">
<AU>de Vries JI, Dekker GA, Huijgens PC, Jakobs C, Blomberg BM, van Geijn HP</AU>
<TI>Hyperhomocysteinaemia and protein s deficiency in complicated pregnancies</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>11</NO>
<PG>1248-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dekker-1995" NAME="Dekker 1995" TYPE="JOURNAL_ARTICLE">
<AU>Dekker GA, de Vries J, Doelitzsch MS, Huijgens PC, von Blomberg B, Jakobs C et al</AU>
<TI>Underlying disorders with severe early-onset preeclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1995</YR>
<VL>173</VL>
<NO>4</NO>
<PG>1042-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dizon_x002d_Townson-1996" NAME="Dizon-Townson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Dizon-Townson DS, Nelson LM, Easton K, Ward K</AU>
<TI>The factor v leiden mutation may predispose women to severe preeclampsia</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>175</VL>
<NO>4 Pt 1</NO>
<PG>902-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dizon_x002d_Townson-1997" NAME="Dizon-Townson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K</AU>
<TI>Fetal carriers of the factor v leiden mutation are prone to miscarriage and placental infarction</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>177</VL>
<NO>2</NO>
<PG>402-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goddijn_x002d_Wessel-1996" NAME="Goddijn-Wessel 1996" TYPE="JOURNAL_ARTICLE">
<AU>Goddijn-Wessel TA, Wooters MG, van de Molen EF, Spuijbroek MD, Steegers-Theunissen RP, Blom HJ, et al</AU>
<TI>Hyperhomocysteinemia: a risk factor for placental abruption or infarction</TI>
<SO>European Journal of Obstetrics, Gynecology and Reproductive Biology</SO>
<YR>1996</YR>
<VL>66</VL>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kahn-1998" NAME="Kahn 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kahn SR</AU>
<TI>Severe preeclampsia associated with coinheritance of factor v leiden mutation and protein S deficiency</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>5 Pt 2</NO>
<PG>812-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krauss-1998" NAME="Krauss 1998" TYPE="JOURNAL_ARTICLE">
<AU>Krauss T, Augustin HG, Osmers R, Meden H, Unterhalt M, Kuhn W</AU>
<TI>Activated protein c resistance and factor v leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>3</NO>
<PG>457-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kupferminc-1999" NAME="Kupferminc 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A et al</AU>
<TI>Increased frequency of genetic thrombophilia in women with complications of pregnancy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<NO>1</NO>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leeda-1998" NAME="Leeda 1998" TYPE="JOURNAL_ARTICLE">
<AU>Leeda M, Riyazi N, de Vries J, Jakobs C, van Geijn HP, Dekker GA</AU>
<TI>Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>179</VL>
<PG>135-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindoff-1997" NAME="Lindoff 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B</AU>
<TI>Preeclampsia is associated with a reduced response to activated protein c</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>2</NO>
<PG>457-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagy-1998" NAME="Nagy 1998" TYPE="JOURNAL_ARTICLE">
<AU>Nagy B, Toth T, Rigo JJ, Karadi I, Romics L, Papp Z</AU>
<TI>Detection of factor v leiden mutation in severe pre-eclamptic Hungarian women</TI>
<SO>Clinical Genetics</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>6</NO>
<PG>478-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Owen-1997" NAME="Owen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Owen EP, Human L, Carolissen AA, Harley EH, Odendaal HJ</AU>
<TI>Hyperhomocysteinemia--a risk factor for abruptio placentae</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>3</NO>
<PG>359-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Powers-1998" NAME="Powers 1998" TYPE="JOURNAL_ARTICLE">
<AU>Powers RW, Evans RW, Majors AK, Ojimba JI, Ness RB, Crombleholme WR, et al</AU>
<TI>Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>179</VL>
<NO>6 Pt 1</NO>
<PG>1605-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Preston-1996" NAME="Preston 1996" TYPE="JOURNAL_ARTICLE">
<AU>Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J et al</AU>
<TI>Increased fetal loss in women with heritable thrombophilia</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9032</NO>
<PG>913-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rajkovic-1997" NAME="Rajkovic 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rajkovic A, Catalano PM, Manilow MR</AU>
<TI>Elevated homocysteine levels with preeclampsia</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>90</VL>
<PG>168-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riyazi-1998" NAME="Riyazi 1998" TYPE="JOURNAL_ARTICLE">
<AU>Riyazi N, Leeda M, de Vries JI, Huijgens PC, van Geijn HP, Dekker GA</AU>
<TI>Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study</TI>
<SO>European Journal of Obstetrics, Gynecology and Reproductive Biology</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>1</NO>
<PG>49-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rotmensch-1997" NAME="Rotmensch 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rotmensch S, Liberati M, Mittlemann M, Ben-Rafael Z</AU>
<TI>Activated protein c resistance and adverse pregnancy outcome</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>177</VL>
<NO>1</NO>
<PG>170-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sohda-1997" NAME="Sohda 1997" TYPE="JOURNAL_ARTICLE">
<AU>Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T</AU>
<TI>Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia</TI>
<SO>Journal of Medical Genetics</SO>
<YR>1997</YR>
<VL>34</VL>
<NO>6</NO>
<PG>525-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiener_x002d_Megnagi-1998" NAME="Wiener-Megnagi 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E</AU>
<TI>Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>179</VL>
<NO>6 Pt 1</NO>
<PG>1565-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2009-10-26 14:54:34 +0000" MODIFIED_BY="Jill V Hampson"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-08-04 00:11:09 +0100" MODIFIED_BY="Jill V Hampson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-08-04 00:11:09 +0100" MODIFIED_BY="Jill V Hampson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Abou_x002d_Nassar-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Abou_x002d_Nassar-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Brenner-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Brenner-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Brenner-2003a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Brenner-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Brenner-2005a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Casele-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Chistolini-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Clemens-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-de-Vries-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Dendrinos-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Gates-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kamin-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Laskin-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rodger-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rodger-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rodger-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rodger-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Tempfer-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Thaler-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Visser-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Visser-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-de-Vries-2000">
<CHAR_STUDY_NAME>
<P>Low molecular weight heparin (FRagmin) in pregnant women with a history of Uteroplacental Insufficiency and Thrombophilia (The FRUIT study).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Pregnant women with a previous history of pre-eclampsia or small for gestational age infants (&lt; 10 percentile) before 34 weeks' gestation and a documented inherited thrombophilia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Low molecular weight heparin (Fragmin) and low dose aspirin (100 mg per day) for treatment group and low dose aspirin only for control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome is reduction in recurrence of pre-eclampsia.<BR/>Secondary outcome is reduction in the recurrence of small for gestational age infants.<BR/>Other endpoints include reduction of spontaneous abortion, preterm birth, maternal admission to the hospital and NICU admission.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION>
<P>JIP de Vries,<BR/>Division of Maternal-Fetal Medicine,<BR/>University Hospital, Free University Amsterdam.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Rodgers-2000">
<CHAR_STUDY_NAME>
<P>Thrombophilia in Pregnancy Prophylaxis Study (TIPPS).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Pregnant women with a documented thrombophilia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Low molecular weight heparin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pre-eclampsia, stillbirth, IUGR, spontaneous abortion, placental abruption, and venous thromboembolism.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>July 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Mark Rodgers,<BR/>Ottawa General Hospital,<BR/>501 Smyth Road,<BR/>Ottawa, Ontario<BR/>Canada<BR/>K1H 8L6.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>NICU: neonatal intensive care unit<BR/>IUGR: intrauterine growth restriction</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK MODIFIED="2008-02-19 15:24:29 +0000" MODIFIED_BY="Sonja Henderson">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2008-02-19 15:24:29 +0000" MODIFIED_BY="Sonja Henderson" NO="1">
<TITLE>Cundiff, July 2007</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>Relevant randomised trials were ongoing at the time of publication of this review. One is now published and compared dalteparin (5,000 units/day until 20 weeks then 5,000 units 12 hourly until 37 weeks or onset of labor) to no treatment [1]. Prophylaxis with dalteparin at doses used in this study did not reduce coagulation activation in high risk thrombophilic women during pregnancy. No clinical data have been reported.</P>
<P>Despite the lack of evidence from randomised trials, opinion-based treatment guidelines for pregnant women with thrombophilia by the Royal College of Obstetricians and Gynaecologists and the American College of Chest Physicians include giving thromboprophylaxis [2, 3].</P>
<P>Given the risks of heparin, the implications for practice section in the review should say that heparin should not be used for pregnant women with acquired or inherited thrombophilias outside of a randomised trial, with either a placebo or antiplatelet agent for the control group.</P>
<P>1. Abou-Nassar K, Kovacs MJ, Kahn SR, et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost 2007; 98(1):163-171.<BR/>2. Thromboprophylaxis during pregnancy, labour and after vaginal delivery. Royal College of Obstetricians and Gynaecologists: London (UK). 2004 (Guideline; no. 37). Available at:<BR/>http://www.rcog.org.uk/resources/Public/pdf/Thromboprophylaxis_no037.pdf.<BR/>3. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3_suppl):627S-644.</P>
<P>(Summary of comment from David K Cundiff, July 2007)</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2008-02-19 15:24:29 +0000" MODIFIED_BY="Sonja Henderson">
<P>We agree with the comment and we will amend the review when we update it.</P>
<P>(Reply from Mark Walker, February 2008)</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2008-02-19 14:51:26 +0000" MODIFIED_BY="Sonja Henderson">
<P>Feedback: David K Cundiff<BR/>Reply: Mark Walker</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2009-10-28 10:23:45 +0000" MODIFIED_BY="Jill V Hampson">
<APPENDIX ID="APP-01" MODIFIED="2009-10-28 10:23:45 +0000" MODIFIED_BY="Jill V Hampson" NO="1">
<TITLE MODIFIED="2009-10-28 10:23:45 +0000" MODIFIED_BY="Jill V Hampson">search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-02-19 14:24:01 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>pregnancy complications/</LI>
<LI>infant mortality/</LI>
<LI>1 or 2</LI>
<LI>exp heparin/</LI>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>exp clinical trials/</LI>
<LI>5 or 6 or 7</LI>
<LI>exp thrombophilia/</LI>
<LI>exp Factor V</LI>
<LI>Factor V deficiency/</LI>
<LI>prothrombin/</LI>
<LI>antiphospholipid syndrome/</LI>
<LI>exp blood coagulation factor inhibitors/</LI>
<LI>exp antibodies, antiphospholipid/</LI>
<LI>exp blood coagulation disorders/</LI>
<LI>hyperhomocysteinemia/</LI>
<LI>or/9-17</LI>
<LI>3 and 4 and 8 and 18</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>